Drug-Resistant Variants That Evolve during Nonsuppressive Therapy Persist in HIV-1-Infected Peripheral Blood Mononuclear Cells after Long-Term Highly Active Antiretroviral Therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 5, 2004, Pages 473-483

  Verhofstede, Chris ^a   Noë, Ann ^a   Demecheleer, Els ^a   De Cabooter, Nancy ^a   Van Wanzeele, Filip ^a   Van Der Gucht, Bea ^a   Vogelaers, Dirk ^a   Plum, Jean ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Drug resistance; Latent reservoir; Persistence of drug resistance; Provirus

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; FEMALE; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROVIRUS; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; PROVIRUSES; SEQUENCE ANALYSIS, PROTEIN; TIME FACTORS; VARIATION (GENETICS);

EID: 1842458366     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200404150-00005     Document Type: Article

References (22)

1. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284-1290.
2. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193-13197.
3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
4. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
5. Persaud D, Pierson T, Ruff C, et al. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest. 2000; 105:995-1003.
6. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
7. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat Med. 2003;9:727-728.
8. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
9. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-593.
10. Strain MC, Gunthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003; 100: 4819-4824.
11. Devereux HL, Youle M, Johnson MA, et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999; 13:F123-F127.
12. Verhofstede C, Wanzeele F, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS. 1999;13:2541-2546.
13. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
14. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type I populations after treatment interruption in patients failing antiretroviral therapy. J Virol. 2001;75:6410-6417.
15. Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS. 2000;14:2247-2255.
16. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-2867.
17. Delaugerre C, Valantin MA, Mouroux M, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS. 2001;15:2189-2191.
18. Izopet J, Souyris C, Hance A, et al. Evolution of human immunodeficiency virus type I populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis. 2002;185: 1506-1510.
19. Becker-Pergola G, Mellquist JL, Eshleman JR, et al. Improved detection of human immunodeficiency virus type 1 variants by analysis of replicate amplification reactions: relevance to studies of human immunodeficiency virus type I vertical transmission. Mol Diagn. 1999;4:261-268.
20. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665-708.
21. Ruff CT, Ray SC, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type I in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76:9481-9492.
22. Frost SD, Nijhuis M, Schuurman R, et al. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol. 2000;74:6262-6268.